ABIOMED, Inc. (NASDAQ:ABMD) Given Consensus Recommendation of Hold by Brokerages – Riverton Roll

Shares of ABIOMED, Inc. (NASDAQ:ABMD) have received an average recommendation of Hold from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $259.33.

A number of analysts recently issued reports on ABMD shares. Morgan Stanley lowered their price target on ABIOMED from $215.00 to $198.00 and set an equal weight rating for the company in a research report on Tuesday, December 17th. William Blair restated a buy rating on shares of ABIOMED in a research report on Monday, September 30th. Leerink Swann raised their price target on ABIOMED from $195.00 to $240.00 and gave the stock an outperform rating in a research report on Friday, November 1st. Raymond James downgraded ABIOMED from an outperform rating to a market perform rating in a research report on Tuesday, October 29th. Finally, BidaskClub lowered ABIOMED from a hold rating to a sell rating in a research note on Tuesday, December 24th.

Shares of ABMD opened at $183.60 on Friday. The company has a market cap of $8.07 billion, a PE ratio of 51.00, a P/E/G ratio of 1.59 and a beta of 0.28. The business has a fifty day moving average of $179.53 and a 200 day moving average of $202.01. ABIOMED has a 52-week low of $155.02 and a 52-week high of $364.31.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, October 31st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts consensus estimates of $0.93 by $0.10. The company had revenue of $204.97 million during the quarter, compared to the consensus estimate of $206.45 million. ABIOMED had a return on equity of 19.89% and a net margin of 26.92%. ABIOMEDs revenue was up 12.8% on a year-over-year basis. During the same period last year, the company earned $1.09 earnings per share. On average, sell-side analysts anticipate that ABIOMED will post 4.31 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in ABMD. BlackRock Inc. increased its stake in ABIOMED by 9.4% in the second quarter. BlackRock Inc. now owns 3,389,676 shares of the medical equipment providers stock worth $882,977,000 after purchasing an additional 290,358 shares during the period. Nuveen Asset Management LLC increased its stake in shares of ABIOMED by 17,845.5% during the second quarter. Nuveen Asset Management LLC now owns 197,759 shares of the medical equipment providers stock valued at $51,514,000 after buying an additional 196,657 shares during the period. Marathon Asset Management LLP purchased a new position in shares of ABIOMED during the third quarter valued at $21,408,000. Amundi Pioneer Asset Management Inc. increased its stake in shares of ABIOMED by 16.7% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 756,488 shares of the medical equipment providers stock valued at $197,057,000 after buying an additional 108,282 shares during the period. Finally, Worldquant Millennium Advisors LLC increased its stake in shares of ABIOMED by 459.8% during the second quarter. Worldquant Millennium Advisors LLC now owns 130,444 shares of the medical equipment providers stock valued at $33,979,000 after buying an additional 107,141 shares during the period. Institutional investors and hedge funds own 90.68% of the companys stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

ABIOMED, Inc. (NASDAQ:ABMD) Given Consensus Recommendation of Hold by Brokerages – Riverton Roll

Categories

Archives